SCHEMBL6760028

SCHEMBL6760028

CNC(=O)CCCN1CCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.45
POLB P06746 1/20 0.45
ALOX15 P16050 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
CARM1 Q86X55 1/20 0.43
PRMT6 Q96LA8 1/20 0.43
PRMT8 Q9NR22 1/20 0.43
HRH3 Q9Y5N1 3/20 0.43
BCHE P06276 1/20 0.43
TERT O14746 2/20 0.43
LMNA P02545 1/20 0.42
HTR1A P08908 1/20 0.42
ADRA2A P08913 1/20 0.42
CYP2D6 P10635 1/20 0.42
ADRA2C P18825 1/20 0.42
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1909619 0.98 CYP1A2 (0.60) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL21443809 0.94 ALDH1A1 (0.51) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL9579322 0.92 ALDH1A1 (0.54) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL9579279 0.91 ALDH1A1 (0.57) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL5109896 0.88 MAPT (0.62) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL12152422 0.86 PAOX (0.55) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL8165558 0.86 MAPT (0.66) CYP1A2MAPK1SMN1; SMN2MAPTALDH1A1
SCHEMBL12847850 0.86 MAPT (0.60) MAPTALDH1A1POLBALOX15L3MBTL1
SCHEMBL17777943 0.83 MAPT (0.57) SMN1; SMN2MAPTALDH1A1POLBALOX15
SCHEMBL9925862 0.83 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019238067-A1 PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2019-12-19 WO disclosed
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use LABORATORIES FOURNIER S.A. (FR) 2004-04-01 US disclosed
EP-1351928-A2 NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER S.A. (FR) 2003-10-15 EP disclosed
WO-2002053516-A2 N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE LABORATOIRES FOURNIER SA (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063725-A1 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use GLS, GLS2, GLRB CYP1A2 4789/4885MAPK1 3459/4885SMN1; SMN2 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.